In this presentation from Retina Subspecialty Day, Dr. David Boyer discusses positive results from the 3-year, multicenter Ozurdex trial. The study assessed the safety and efficacy of the dexamethasone posterior segment drug delivery system (Dex PS DDS) in the treatment of patients with diabetic macular edema (DME). The biodegradable system delivers low doses of intravitreal dexamethasone for prolonged periods.

.